NO20004350L - Preparat med vedvarende frigivinng av AII-antagonist, fremstilling og anvendelse herav - Google Patents

Preparat med vedvarende frigivinng av AII-antagonist, fremstilling og anvendelse herav

Info

Publication number
NO20004350L
NO20004350L NO20004350A NO20004350A NO20004350L NO 20004350 L NO20004350 L NO 20004350L NO 20004350 A NO20004350 A NO 20004350A NO 20004350 A NO20004350 A NO 20004350A NO 20004350 L NO20004350 L NO 20004350L
Authority
NO
Norway
Prior art keywords
preparation
sustained release
aii antagonist
angiotensin
sustained
Prior art date
Application number
NO20004350A
Other languages
English (en)
Other versions
NO20004350D0 (no
Inventor
Yasutaka Igari
Akira Saikawa
Yoshiyuki Inada
Shigeru Kamei
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO20004350D0 publication Critical patent/NO20004350D0/no
Publication of NO20004350L publication Critical patent/NO20004350L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Den foreliggende oppfinnelsen tilveiebringer et preparat med vedvarende frigivmng som omfatter en forbindelse med angiotensin U antagonistisk virkning, dets pro-drug eller deres salter, og en bionedbrytbar polymer, og hvis nødvendig et polyvalent metall, og som er fremdeles stabil og aktiv og utviser angiotensin H antagonistisk virkning med opprettholdt sirkadian blodtrykksrytme i lang tid.
NO20004350A 1998-03-04 2000-09-01 Preparat med vedvarende frigivinng av AII-antagonist, fremstilling og anvendelse herav NO20004350L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP5236698 1998-03-04
PCT/JP1999/001011 WO1999044590A1 (en) 1998-03-04 1999-03-03 Sustained-release preparation for aii antagonist, production and use thereof

Publications (2)

Publication Number Publication Date
NO20004350D0 NO20004350D0 (no) 2000-09-01
NO20004350L true NO20004350L (no) 2000-10-03

Family

ID=12912818

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004350A NO20004350L (no) 1998-03-04 2000-09-01 Preparat med vedvarende frigivinng av AII-antagonist, fremstilling og anvendelse herav

Country Status (21)

Country Link
US (2) US6589547B1 (no)
EP (1) EP1058541B1 (no)
KR (1) KR20010086245A (no)
CN (1) CN1291888A (no)
AT (1) ATE258430T1 (no)
AU (1) AU2745199A (no)
BR (1) BR9908474A (no)
CA (1) CA2318446C (no)
DE (1) DE69914460T2 (no)
EE (1) EE200000499A (no)
ES (1) ES2214013T3 (no)
HU (1) HUP0101439A3 (no)
ID (1) ID25640A (no)
IL (1) IL137979A0 (no)
LT (1) LT4800B (no)
LV (1) LV12585B (no)
NO (1) NO20004350L (no)
PL (1) PL342684A1 (no)
SK (1) SK11902000A3 (no)
WO (1) WO1999044590A1 (no)
ZA (1) ZA991706B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID25640A (id) * 1998-03-04 2000-10-19 Takeda Chemical Industries Ltd Preparat pelepasan terus menerus untuk antagonistik aii, produksi dan penggunaannya
PT1197223E (pt) 1999-04-28 2005-04-29 Takeda Pharmaceutical Preventivos/medicamentos/inibidores da progressao de retinopatia simples ou retinopatia pre-proliferativa
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
US6833381B2 (en) * 2000-02-18 2004-12-21 Takeda Chemical Industries, Ltd. TNF-α inhibitors
CA2400845A1 (en) * 2000-02-21 2001-08-23 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active compound slightly soluble in water and production process and use of the same
EP1312379A4 (en) * 2000-08-25 2004-08-25 Takeda Chemical Industries Ltd FIBRINOGENIC REDUCTION AGENTS
WO2002034263A1 (fr) * 2000-10-25 2002-05-02 Takeda Chemical Industries, Ltd. Agents preventifs/remedes destines a l'hypertension portale
WO2002074340A1 (fr) * 2001-03-16 2002-09-26 Takeda Chemical Industries, Ltd. Procede de fabrication d'une preparation a liberation continue
CA2456034A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
BRPI0105509B8 (pt) * 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
WO2003041739A1 (en) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticaner agents
EP1452176A4 (en) * 2001-12-03 2009-01-21 Takeda Pharmaceutical MEANS FOR IMPROVING INSULIN RESISTANCE
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
EP1579872B8 (en) * 2002-12-27 2012-11-07 Takeda Pharmaceutical Company Limited Body weight gain inhibitor
US20050038093A1 (en) * 2003-05-02 2005-02-17 Boehringer Ingelheim International Gmbh Treating diabetic retinopathy with angiotensin II receptor blockers
CN1795198B (zh) * 2003-05-29 2011-08-17 杰伊·W·佩特格尤 对神经精神疾病进行医学成像所用的甘油磷酸胆碱及其衍生物
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
WO2005097109A1 (en) * 2004-04-01 2005-10-20 Daniel Batlle Methods for achieving a protective ace2 expression level
PL1750862T3 (pl) 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
AR052015A1 (es) * 2004-10-07 2007-02-28 Takeda Pharmaceutical Agente para la profilaxis o tratamiento del sindrome metabolico
WO2006046528A1 (ja) * 2004-10-29 2006-05-04 Kowa Co., Ltd. 糸球体疾患治療剤
CA2598410A1 (fr) * 2005-02-21 2006-08-24 Flamel Technologies Forme pharmaceutique orale de losartan
PE20061195A1 (es) * 2005-03-30 2006-12-21 Takeda Pharmaceutical Derivado de bencimidazol como antagonista de angiotensina ii
CA2619955A1 (en) * 2005-08-22 2007-03-22 Alembic Limited Process for preparing valsartan
JP5361188B2 (ja) * 2006-08-10 2013-12-04 武田薬品工業株式会社 医薬組成物
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
PE20081364A1 (es) * 2006-09-04 2008-12-04 Novartis Ag Composicion farmaceutica que comprende valsartan
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CN101563068B (zh) 2006-12-18 2013-03-20 武田药品工业株式会社 缓释组合物和其制备方法
CN101011393B (zh) * 2007-02-16 2010-10-06 广州柏赛罗药业有限公司 厄贝沙坦胃内滞留型缓释药物组合物
MX2009010167A (es) * 2007-03-28 2009-10-12 Takeda Pharmaceutical Composicion farmaceutica solida que comprende un derivado de bencimidazol-7-carboxilato y un agente para el control del ph.
WO2009134057A2 (ko) * 2008-04-29 2009-11-05 한올제약주식회사 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
CA2761576C (en) 2009-05-20 2017-08-22 Boehringer Ingelheim Vetmedica Gmbh Oral suspension comprising telmisartan
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2751907A (en) * 1953-09-18 1956-06-26 Bishop & Co Platinum Works J Pellet injector
JPS5671074A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
IE802177L (en) 1980-10-21 1981-05-12 Takeda Chemical Industries Ltd Imidazol-5-ylacetic acid derivatives
JPS58157768A (ja) 1982-03-16 1983-09-19 Takeda Chem Ind Ltd ４−クロロ−２−フエニルイミダゾ−ル−５−酢酸誘導体
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4820843A (en) 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US4880804A (en) 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US4898732A (en) * 1988-05-04 1990-02-06 The Clinipad Corporation Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system
DE3928177A1 (de) 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
DE69010076T2 (de) * 1989-05-25 1994-12-08 Takeda Chemical Industries Ltd Transdermales therapeutisches Mittel.
EP0403158A3 (en) 1989-06-14 1991-12-18 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
WO1991000277A1 (en) 1989-06-30 1991-01-10 E.I. Du Pont De Nemours And Company Substituted imidazoles
CA2020073A1 (en) 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
EP0407342A3 (en) 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
EP0409332A3 (en) 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
ATE113281T1 (de) 1989-08-02 1994-11-15 Takeda Chemical Industries Ltd Pyrazol-derivate, verfahren zu deren herstellung und anwendung.
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
EP0434038A1 (en) 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Fused imidazole derivatives, their production and use
CA2036304C (en) 1990-02-15 2001-04-17 Takehiko Naka Pyrimidinedione derivatives, their production and use
CA2036618C (en) * 1990-02-22 2002-10-29 Akira Morimoto Fused thiophene derivatives, their production and use
IL99246A0 (en) * 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
TW274551B (no) 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
CZ36394A3 (en) * 1991-08-19 1994-07-13 Du Pont Substituted imidazilonone derivatives and pharmaceutical preparations based thereon
TW284688B (no) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
GB2272899A (en) * 1992-11-30 1994-06-01 Du Pont Merck Pharma Angiotensin-11 receptor blocking cycloalkylbenzylimidazoles
DE69330593T2 (de) 1992-12-22 2002-06-27 Takeda Chemical Industries Ltd Heterocyclische Verbindungen mit Angiotensin-II-antagonistischer Wirkung und ihre Anwendung
US5288720A (en) * 1993-04-23 1994-02-22 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
ATE420628T1 (de) * 1993-07-19 2009-01-15 Angiotech Pharm Inc Anti-angiogene mittel und verfahren zu deren verwendung
JPH0789849A (ja) 1993-09-20 1995-04-04 Fujisawa Pharmaceut Co Ltd 徐放性製剤
CA2224381A1 (en) * 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
UY24504A1 (es) 1996-03-29 1997-09-19 Smithkline Beecham Corp Dihidrato de eprosartano y un procedimiento para su produccion y formulacion
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6201002B1 (en) * 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US5958884A (en) * 1997-04-11 1999-09-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating erectile dysfunction
US6306826B1 (en) * 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
ID25640A (id) * 1998-03-04 2000-10-19 Takeda Chemical Industries Ltd Preparat pelepasan terus menerus untuk antagonistik aii, produksi dan penggunaannya

Also Published As

Publication number Publication date
US7294344B2 (en) 2007-11-13
US20030198676A1 (en) 2003-10-23
ES2214013T3 (es) 2004-09-01
WO1999044590A1 (en) 1999-09-10
EP1058541B1 (en) 2004-01-28
KR20010086245A (ko) 2001-09-10
PL342684A1 (en) 2001-07-02
CN1291888A (zh) 2001-04-18
DE69914460D1 (de) 2004-03-04
LV12585A (en) 2000-12-20
LT2000082A (en) 2001-03-26
CA2318446A1 (en) 1999-09-10
IL137979A0 (en) 2001-10-31
LV12585B (en) 2001-03-20
BR9908474A (pt) 2000-12-05
US6589547B1 (en) 2003-07-08
HUP0101439A2 (hu) 2001-10-28
SK11902000A3 (sk) 2001-02-12
LT4800B (lt) 2001-06-25
CA2318446C (en) 2008-09-23
HUP0101439A3 (en) 2002-09-30
ATE258430T1 (de) 2004-02-15
NO20004350D0 (no) 2000-09-01
AU2745199A (en) 1999-09-20
ZA991706B (en) 2000-10-03
DE69914460T2 (de) 2004-10-28
ID25640A (id) 2000-10-19
EE200000499A (et) 2002-02-15
EP1058541A1 (en) 2000-12-13

Similar Documents

Publication Publication Date Title
NO20004350L (no) Preparat med vedvarende frigivinng av AII-antagonist, fremstilling og anvendelse herav
DK1741398T3 (da) Ortopædisk implantatsamling omfattende stopelement og sikringselement
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
DK1327440T5 (da) Orale pr parater med gunstige nedbrydningsegenskaber
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
BR0010914A (pt) Composto medicamento agente profilático ou terapêutico, e, uso do composto
EA200601591A1 (ru) Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
BR0010869A (pt) Método para administrar um corticosteróide a um segmento posterior de um olho e dispositivo de liberação sustentada implantável
BR0101264A (pt) Derivados de diazepan ou seus sais
BR0209327A (pt) Composição para tratamento de constipação induzida por drogas
BR0112770A (pt) Agentes herbicidas
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
BRPI0407949A (pt) composição ativa herbicida, agente herbicida, método para controlar vegetação indesejável, e, uso de composições
BR0013943A (pt) Conjugados de glicopiranosìdeos de 2-(4-hidróxi-fenil)-1-[4-(2-amin-1-il-etóxi)-benzil]-1h-indo l-5-óis
HUP0202226A2 (hu) Eljárás rovarkártevők elleni védekezésre
BR0014610A (pt) Combinações de compostos ativos tendo propriedades inseticidas e acaricidas
DK1152776T3 (da) Bionedbrydelig, injicerbar oligomer-polymer-sammensætning
DK1174131T3 (da) Anvendelse af et middel til forbedring af astrocytfunktion til behandling af Parkinsons sygdom
BR9910305A (pt) Vacina
WO2003028464A1 (fr) Composition herbicide
EP1430776A4 (en) HERBICIDE COMPOSITION
NO20044463L (no) Forbedret modifisert-frigjoringspreparat
PT1330246E (pt) Utilizacao de derivados do acido hidroxieicosatetraenoico em cirurgia intraocular
DE60214987D1 (de) Mittel gegen posttraumatische stresszustände